Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients with advanced EGFR mutation-positive non-small-cell lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Murakami, Haruyasu, Ohe, Yuichiro, Hida, Toyoaki, Sakai, Hiroshi, Kasahara, Kazuo, Imamura, Fumio, Baba, Tomohisa, Kubota, Kaoru, Hosomi, Yukio, Shimokawa, Tsuneo, Hayashi, Hidetoshi, Miyadera, Kazutaka, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856039/
https://www.ncbi.nlm.nih.gov/pubmed/30790152
http://dx.doi.org/10.1007/s10637-019-00732-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856039/
https://www.ncbi.nlm.nih.gov/pubmed/30790152
http://dx.doi.org/10.1007/s10637-019-00732-4

Ejemplares similares